These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23201153)

  • 1. Real-world experience with posaconazole prophylaxis in high-risk hematological patients in Singapore: a prospective audit.
    Low CY; Ong WC; Wong E; Ding Y; Diong CP; Jin J; Lim ZY; Hsu LY
    J Infect; 2013 Mar; 66(3):291-4. PubMed ID: 23201153
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
    Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
    Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
    Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
    Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
    Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
    Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
    J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT.
    Molina JR; Serrano J; Sánchez-García J; Rodríguez-Villa A; Gómez P; Tallón D; Martín V; Rodríguez G; Rojas R; Martín C; Martínez F; Alvarez MA; Torres A
    Bone Marrow Transplant; 2012 Apr; 47(4):562-7. PubMed ID: 21572466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
    Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
    J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients.
    Cesaro S; Milano GM; Aversa F
    Eur J Clin Microbiol Infect Dis; 2011 Apr; 30(4):595-6. PubMed ID: 21120565
    [No Abstract]   [Full Text] [Related]  

  • 15. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.
    Uzun O; Anaissie EJ
    Blood; 1995 Sep; 86(6):2063-72. PubMed ID: 7662953
    [No Abstract]   [Full Text] [Related]  

  • 16. Antifungal prophylaxis in the haematological patient: a practical approach.
    Vázquez L; Carreras E; Serrano D; Jarque I; Mensa J; Barberán J
    Rev Esp Quimioter; 2012 Dec; 25(4):299-304. PubMed ID: 23303265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
    Frick MA; Soler-Palacín P; Martín Nalda A; Guarner ME; Nadal CF
    Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
    [No Abstract]   [Full Text] [Related]  

  • 18. Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?
    Girmenia C; Annino L; Mariotti B; Fanci R; Minotti C; Spadea A; Carotti A; Piedimonte M; Chierichini A; Cerchiara E; Caselli D; Cupelli L; Arcioni F; Bertaina A; Ribersani M; Proia A; Mengarelli A; Perriello V; Torelli GF; Di Gioia M; Del Principe MI; Cassetta MI; Fallani S; Novelli A
    Med Mycol; 2016 Jul; 54(5):445-58. PubMed ID: 26868905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Level of evidence for therapeutic drug monitoring of posaconazole].
    Lefeuvre S; Jelassi ML; Benlmouden A; Berge M; Le Guellec C; Billaud EM;
    Therapie; 2011; 66(2):115-22. PubMed ID: 21635858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.